Pharmacokinetics of methadone in human-immunodeficiency-virus-infected patients receiving nevirapine once daily

European Journal of Clinical Pharmacology

Volumn 63, Issue 7, 2007, Pages 669-675

  Arroyo, Elena ^a,b,c   Valenzuela, Belén ^b   Portilla, Joaquín ^a   Climent Grana, Eduardo ^a,b   Pérez Ruixo, Juan José ^b   Merino, Esperanza ^a  

^a HOSPITAL GENERAL UNIVERSITARIO DE ALICANTE   (Spain)

^b MIGUEL HERNÁNDEZ UNIVERSITY   (Spain)

^c AVDA   (Spain)

Author keywords

Drug drug interaction; EDDP; HIV; Methadone; Nevirapine

Indexed keywords

2 ETHYLIDENE 1,5 DIMETHYL 3,3 DIPHENYLPYRROLIDINE; DIDANOSINE; DRUG METABOLITE; METHADONE; NEVIRAPINE; STAVUDINE; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CRYING; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG METABOLISM; DRUG USE; DRUG WITHDRAWAL; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; INSOMNIA; MALE; MAXIMUM PLASMA CONCENTRATION; MYALGIA; PRIORITY JOURNAL; REFLEX; RHINORRHEA; STATISTICAL SIGNIFICANCE; SWEATING; WITHDRAWAL SYNDROME; YAWNING;

ADULT; ANALGESICS, OPIOID; ANALYSIS OF VARIANCE; ANTI-HIV AGENTS; AREA UNDER CURVE; DRUG INTERACTIONS; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MALE; METHADONE; NEVIRAPINE; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 34250312452     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00228-007-0299-z     Document Type: Article

References (26)

1. Murphy RL, Montaner J (1996) Nevirapine: a review of its development, pharmacological profile and potential for clinical use. Exp Opin Invest Drugs 5:1183-1199
2. Anonymous (1996) Nevirapine tablets, Viramune tablets. Summary basis of approval equivalent. FDA Summary Basis of Approval
3. Havlir D, Cheesman SH, McLaughlin W et al (1995) High dose nevirapine: safety, pharmacokinetics, and antiviral effects in patients with HIV infection. J Infect Dis 171:537-545
4. Riska P, Lamson M, MacGregor T et al (1999) Disposition and biotransformation of the antiretroviral drug nevirapine in humans. Drug Metab Dispos 27:895-901
5. Stocker H, Kruse G, Kreckel P et al (2004) Nevirapine significantly reduces the levels of racemic methadone and (R)-methadone in human immunodeficiency virus-infected patients. Antimicrob Agent Chemother 48:4148-4153
6. Dole V, Nyswander M (1965) A medical treatment for diacetylmorphine (heroin) addiction. JAMA 193:646-650
7. NIH Consensus Conference (1998) Effective medical treatment of opiate addiction. JAMA 280:1936-1943
8. Kreek MJ, Vocci FJ (2002) History and current status of opioid maintenance treatments: blending conference session. J Subst Abuse Treat 23:93-105
9. Iribarne C, Berthou F, Baird S et al (1996) Involvement of cyctochrome P450 3A4 enzyme in the N-demethylation of methadone in human liver microsomes. Chem Res Toxicol 9:365-373
10. Wang JS, DeVane CL (2003) Involvement of CYP3A4, CYP2C8, and CYP2D6 in the metabolism of (R)-and (S)-methadone in vitro. Drug Metab Dispos 31:742-747
11. Gerber JG, Rhodes RJ, Gal J (2004) Stereoselective metabolism of methadone N-demethylation by cytochrome P4502B6 and 2C19. Chirality 16:36-44
12. Beckett AH, Taylor JF, Casy AF, Hassan MM (1968) The biotransformation of methadone in man: synthesis and identification of a major metabolite. J Pharm Pharmacol 20:754-762
13. Altice FL, Friedland GH, Cooney EL (1999) Nevirapine induced opiate withdrawal among injection drug users with HIV infection receiving methadone. AIDS 13:957-962
14. Heelon MW, Meade LB (1999) Methadone withdrawal when starting an antiretroviral regimen including nevirapine. Pharmacotherapy 19:471-472
15. Pinzani V, Faucherre V, Peyriere H, Blayac JP (2000) Methadone withdrawal symptoms with nevirapine and efavirenz. Ann Pharmacother 34:405-407
16. Clarke SM, Mulcahy FM, Tjia J et al (2001) Pharmacokinetic interactions of nevirapine and methadone and guidelines for use of nevirapine to treat injection drug users. Clin Infect Dis 33:1595-1597
17. van Leth F, Phanuphak P, Ruxrungtham K et al (2004) Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study. Lancet 363:1253-1263
18. van Heeswijk RP, Veldkamp AI, Mulder JW et al (2000) The steady-state pharmacokinetics of nevirapine during once daily and twice daily dosing in HIV-1-infected individuals. AIDS 14:77-82
19. Crommentuyn KM, Huitema AD, Brinkman K, van der Ende ME, de Wolf F, Beijnen JH, Athena study (2001) Nevirapine once daily versus twice daily: implications for drug-drug interactions. 2nd International Workshop on Clinical Pharmacology of HIV Therapy, April 2-4; Noordwijk, Holland. http://www.natap. org/2001/2ndworkshop/nvp_oncedaily041601.htm
20. Torrens M, Castillo C, San L, del Moral E, Gonzalez ML, de la Torre R (1998) Plasma methadone concentrations as an indicator of opioid withdrawal symptoms and heroin use in a methadone maintenance program. Drug Alcohol Depend 52:193-200
21. Gibaldi M, Perrier D (1982) Appendix D. Estimation of areas. In: Pharmacokinetics. Marcel Dekker, New York, pp 445-449
22. Kharasch ED, Hoffer C, Whittington D, Sheffels P (2004) Role of hepatic and intestinal cytochrome P4503A and 2B6 in the metabolism, disposition, and miotic effects of methadone. Clin Pharmacol Ther 76:250-269
23. Crettol S, Déglon JJ, Besson J et al (2005) Methadone enantiomer plasma levels CYP2B6, CYP2C19, CYP2C9 genotypes, and response to treatment. Clin Pharmacol Ther 78:593-604
24. Faucette SR, Zhang TC, Moore R et al (2007) Relative activation of human pregnane X receptor versus constitutive androstane receptor defines distinct classes of CYP2B6 and CYP3A4 inducers. J Pharmacol Exp Ther 320:72-80
25. Otero MJ, Fuertes A, Sánchez R, Luna G (1999) Nevirapine induced withdrawal symptoms in HIV patients on methadone maintenance programmes-an alert. AIDS 13:1004-1005
26. Barry M, Feely J (1990) Enzyme induction and inhibition. Pharmacol Ther 48:71-94